• Reducir tamaño del texto
  • Reducir tamaño del texto
CIMA Oncology Neurosciences Cardiovascular sciences Gene therapy & Hepatology division

communication


09/08/2008


Researchers from the University of Navarra’s CIMA have discovered a genetic anomaly that could increase the risk of thrombosis



Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra have identified a genetic anomaly that may increase the risk of thrombosis. The European Haematology Association has published the resulting article, which will also grace the cover of its journal Haematologica.

The endothelial protein C receptor (EPCR) plays an anticoagulant function in the cells of the blood vessels. Nevertheless, when they are transformed to be soluble (sEPCR), they become a factor that promotes coagulation. “Our study has determined that this alteration may have its origin in a new system of genetic diversification (alternative splicing). The detection of this molecule could thus become a new tool for evaluating thrombotic risk,” explained Ramón Montes, Lead Researcher.

The research project, with co-participants Eva Molina, José Hermida, Jacinto López-Sagaseta and Cristina Puy, of the area of Cardiovascular Sciences, has also demonstrated the presence of sEPCR in lung cancer cellular lines. “The data obtained in our study,” indicated Ramón Montes, “leads us to think that the incidence of thrombosis in cancer patients may be due to the presence of this molecule. If this were the case, we would have a possible marker for lung cancer.”

Article 
Top
CIMA new
First line, from left to right: José Hermida, Ramón Montes and Jacinto López. Second line: Maider Esparza, Eva Molina, Jorge Cervero, Mikel Allende and Cristina Puy.
Photo: Manuel Castells [+]
LEGAL NOTE   |   SITE MAP